Xeris Biopharma’s (XERS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Xeris Biopharma (NASDAQ:XERS) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Xeris Biopharma’s Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.17 EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.66 EPS and FY2030 earnings at $0.91 EPS.

XERS has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Oppenheimer reiterated an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Piper Sandler raised their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Finally, Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.08.

Xeris Biopharma Stock Up 2.2%

Xeris Biopharma stock opened at $6.07 on Monday. The stock has a 50 day moving average of $7.16 and a two-hundred day moving average of $7.61. Xeris Biopharma has a twelve month low of $3.65 and a twelve month high of $10.08. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -606.39 and a beta of 0.61. The company has a current ratio of 2.19, a quick ratio of 1.35 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. As a group, research analysts expect that Xeris Biopharma will post -0.41 earnings per share for the current year.

Insider Buying and Selling at Xeris Biopharma

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $7.09, for a total value of $106,350.00. Following the sale, the director directly owned 142,500 shares in the company, valued at $1,010,325. The trade was a 9.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the sale, the insider directly owned 2,705,346 shares in the company, valued at approximately $19,153,849.68. The trade was a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 240,308 shares of company stock worth $1,732,453. Insiders own 6.47% of the company’s stock.

Institutional Trading of Xeris Biopharma

Large investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its stake in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares in the last quarter. Millennium Management LLC raised its position in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP purchased a new position in shares of Xeris Biopharma during the first quarter valued at approximately $170,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Analyst support — HC Wainwright reiterated a “Buy” rating and a $10 price target while publishing multi-year EPS models that show the company returning to positive earnings by FY2026 and rising thereafter; that bullish stance supports investor optimism. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Earnings beat — Xeris reported Q4 2025 adjusted EPS above consensus (roughly $0.0615 vs. $0.03 expected), indicating improving profitability that investors are rewarding. Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
• Positive Sentiment: Bull thesis coverage — A Seeking Alpha piece argues Xeris is undervalued given its drug portfolio upside, which can attract value-oriented and growth investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Neutral Sentiment: Profitability vs. legal risk — Coverage highlights that Xeris has achieved new profitability metrics but is simultaneously engaged in patent disputes over Recorlev; this balances upside with legal uncertainty, creating a mixed signal for investors. Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
• Negative Sentiment: Insider sale — Director/insider Beth Hecht sold 16,667 shares at about $6.25 on March 2, modestly reducing her stake; insider selling can raise caution among investors even if the position remains large. SEC Form 4 — Beth Hecht
• Negative Sentiment: Analyst estimate cuts — Although HC Wainwright kept a Buy rating, it trimmed several multi-year EPS forecasts (FY2026–FY2029/FY2030 adjustments), which reduces the magnitude of long-term upside implied by prior models. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.